Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 563 entries
Sorted by: Best Match Show Resources per page
A novel del(8)(q23.2q24.11) contributing to disease progression in a case of JAK2/TET2 double mutated chronic myelomonocytic leukemia.

Leukemia research reports

Toft-Petersen M, Kjeldsen E, Nederby L, Grønbæk K, Hokland P, Roug AS.
PMID: 25473623
Leuk Res Rep. 2014 Nov 13;3(2):94-7. doi: 10.1016/j.lrr.2014.09.002. eCollection 2014.

We have identified a novel 7.7 Mb del(8)(q23.2q24.11) in a patient progressing to acute myeloid leukemia (AML) following a 12-year stable phase of chronic myelomonocytic leukemia (CMML). A surprisingly high JAK2+ allelic burden of 92% at the time of...

Cite
Toft-Petersen M, Kjeldsen E, Nederby L, et al. A novel del(8)(q23.2q24.11) contributing to disease progression in a case of JAK2/TET2 double mutated chronic myelomonocytic leukemia. Leuk Res Rep. 2014;3(2):94-7doi: 10.1016/j.lrr.2014.09.002.
Toft-Petersen, M., Kjeldsen, E., Nederby, L., Grønbæk, K., Hokland, P., & Roug, A. S. (2014). A novel del(8)(q23.2q24.11) contributing to disease progression in a case of JAK2/TET2 double mutated chronic myelomonocytic leukemia. Leukemia research reports, 3(2), 94-7. https://doi.org/10.1016/j.lrr.2014.09.002
Toft-Petersen, Marie, et al. "A novel del(8)(q23.2q24.11) contributing to disease progression in a case of JAK2/TET2 double mutated chronic myelomonocytic leukemia." Leukemia research reports vol. 3,2 (2014): 94-7. doi: https://doi.org/10.1016/j.lrr.2014.09.002
Toft-Petersen M, Kjeldsen E, Nederby L, Grønbæk K, Hokland P, Roug AS. A novel del(8)(q23.2q24.11) contributing to disease progression in a case of JAK2/TET2 double mutated chronic myelomonocytic leukemia. Leuk Res Rep. 2014 Nov 13;3(2):94-7. doi: 10.1016/j.lrr.2014.09.002. eCollection 2014. PMID: 25473623; PMCID: PMC4250842.
Copy Download .nbib Format: NLM
A molecular risk score integrating BAALC, ERG and WT1 expression levels for risk stratification in acute promyelocytic leukemia.

Leukemia research

Hecht A, Nowak D, Nowak V, Hanfstein B, Büchner T, Spiekermann K, Weiß C, Hofmann WK, Lengfelder E, Nolte F.
PMID: 26344466
Leuk Res. 2015 Aug 20; doi: 10.1016/j.leukres.2015.08.010. Epub 2015 Aug 20.

To date risk stratification in acute promyelocytic leukemia (APL) is based on highly dynamic leukocyte and platelet counts only. To identify a more robust risk stratification model, a molecular risk score was developed based on expression levels of the...

Cite
Hecht A, Nowak D, Nowak V, et al. A molecular risk score integrating BAALC, ERG and WT1 expression levels for risk stratification in acute promyelocytic leukemia. Leuk Res. 2015;doi: 10.1016/j.leukres.2015.08.010.
Hecht, A., Nowak, D., Nowak, V., Hanfstein, B., Büchner, T., Spiekermann, K., Weiß, C., Hofmann, W. K., Lengfelder, E., & Nolte, F. (2015). A molecular risk score integrating BAALC, ERG and WT1 expression levels for risk stratification in acute promyelocytic leukemia. Leukemia research, . https://doi.org/10.1016/j.leukres.2015.08.010
Hecht, Anna, et al. "A molecular risk score integrating BAALC, ERG and WT1 expression levels for risk stratification in acute promyelocytic leukemia." Leukemia research vol. (2015). doi: https://doi.org/10.1016/j.leukres.2015.08.010
Hecht A, Nowak D, Nowak V, Hanfstein B, Büchner T, Spiekermann K, Weiß C, Hofmann WK, Lengfelder E, Nolte F. A molecular risk score integrating BAALC, ERG and WT1 expression levels for risk stratification in acute promyelocytic leukemia. Leuk Res. 2015 Aug 20; doi: 10.1016/j.leukres.2015.08.010. Epub 2015 Aug 20. PMID: 26344466.
Copy Download .nbib Format: NLM
Characteristics of Adult T-Cell Leukemia/Lymphoma Patients with Long Survival: Prognostic Significance of Skin Lesions and Possible Beneficial Role of Valproic Acid.

Leukemia research and treatment

Yves P, Stephane M, Rishika B, Christine D, Gérard P.
PMID: 26199759
Leuk Res Treatment. 2015;2015:476805. doi: 10.1155/2015/476805. Epub 2015 Jun 14.

We describe the clinical and biological features of ten patients with a survival superior to ten years (long survival), out of 175 patients diagnosed with Adult T-cell Leukemia/Lymphoma (ATL) in Martinique (1983-2013). There were 5 lymphoma and 5 chronic...

Cite
Yves P, Stephane M, Rishika B, et al. Characteristics of Adult T-Cell Leukemia/Lymphoma Patients with Long Survival: Prognostic Significance of Skin Lesions and Possible Beneficial Role of Valproic Acid. Leuk Res Treatment. 2015;2015:476805doi: 10.1155/2015/476805.
Yves, P., Stephane, M., Rishika, B., Christine, D., & Gérard, P. (2015). Characteristics of Adult T-Cell Leukemia/Lymphoma Patients with Long Survival: Prognostic Significance of Skin Lesions and Possible Beneficial Role of Valproic Acid. Leukemia research and treatment, 2015476805. https://doi.org/10.1155/2015/476805
Yves, Plumelle, et al. "Characteristics of Adult T-Cell Leukemia/Lymphoma Patients with Long Survival: Prognostic Significance of Skin Lesions and Possible Beneficial Role of Valproic Acid." Leukemia research and treatment vol. 2015 (2015): 476805. doi: https://doi.org/10.1155/2015/476805
Yves P, Stephane M, Rishika B, Christine D, Gérard P. Characteristics of Adult T-Cell Leukemia/Lymphoma Patients with Long Survival: Prognostic Significance of Skin Lesions and Possible Beneficial Role of Valproic Acid. Leuk Res Treatment. 2015;2015:476805. doi: 10.1155/2015/476805. Epub 2015 Jun 14. PMID: 26199759; PMCID: PMC4496652.
Copy Download .nbib Format: NLM
Four hepatosplenic T-cell lymphoma cases of Japanese patients.

Leukemia research reports

Kawai H, Matsushita H, Ohmachi K, Kojima M, Machida S, Ogawa Y, Kawada H, Nakamura N, Ando K.
PMID: 26870659
Leuk Res Rep. 2015 Dec 15;5:3-6. doi: 10.1016/j.lrr.2015.12.001. eCollection 2016.

Hepatosplenic T-cell lymphoma (HSTCL), a rare type of γδ T-cell lymphoma, is characterized by hepatosplenomegaly and cytopenias. It is associated with immunodeficiency and its age of onset is reportedly between the 20s and 30s. We herein report 4 Japanese...

Cite
Kawai H, Matsushita H, Ohmachi K, et al. Four hepatosplenic T-cell lymphoma cases of Japanese patients. Leuk Res Rep. 2015;5:3-6doi: 10.1016/j.lrr.2015.12.001.
Kawai, H., Matsushita, H., Ohmachi, K., Kojima, M., Machida, S., Ogawa, Y., Kawada, H., Nakamura, N., & Ando, K. (2016). Four hepatosplenic T-cell lymphoma cases of Japanese patients. Leukemia research reports, 53-6. https://doi.org/10.1016/j.lrr.2015.12.001
Kawai, Hidetsugu, et al. "Four hepatosplenic T-cell lymphoma cases of Japanese patients." Leukemia research reports vol. 5 (2016): 3-6. doi: https://doi.org/10.1016/j.lrr.2015.12.001
Kawai H, Matsushita H, Ohmachi K, Kojima M, Machida S, Ogawa Y, Kawada H, Nakamura N, Ando K. Four hepatosplenic T-cell lymphoma cases of Japanese patients. Leuk Res Rep. 2015 Dec 15;5:3-6. doi: 10.1016/j.lrr.2015.12.001. eCollection 2016. PMID: 26870659; PMCID: PMC4711307.
Copy Download .nbib Format: NLM
[In Process Citation].

Leukemia research

Gisslinger H, Penka M.
PMID: 27130523
Leuk Res. 2016 May;44:v. doi: 10.1016/S0145-2126(16)30070-4. Epub 2016 Apr 26.

No abstract available.

Cite
Gisslinger H, Penka M. [In Process Citation]. Leuk Res. 2016;44:vdoi: 10.1016/S0145-2126(16)30070-4.
Gisslinger, H., & Penka, M. (2016). [In Process Citation]. Leukemia research, 44v. https://doi.org/10.1016/S0145-2126(16)30070-4
Gisslinger, Heinz, and Penka, Miroslav. "[In Process Citation]." Leukemia research vol. 44 (2016): v. doi: https://doi.org/10.1016/S0145-2126(16)30070-4
Gisslinger H, Penka M. [In Process Citation]. Leuk Res. 2016 May;44:v. doi: 10.1016/S0145-2126(16)30070-4. Epub 2016 Apr 26. PMID: 27130523.
Copy Download .nbib Format: NLM
Kinetics of del(7q) driven leukemogenesis in a patient with JAK2 V617F and TET2 mutated chronic myeloproliferative neoplasm.

Leukemia research reports

Herborg LL, Nederby L, Kjeldsen E, Grønbæk K, Hokland P, Hansen M, Celik Hansen M, Roug AS.
PMID: 24371780
Leuk Res Rep. 2013 Jul 04;2(2):51-3. doi: 10.1016/j.lrr.2013.06.001. eCollection 2013.

Chronic myeloid neoplasms have susceptibility to transform into acute myeloid leukemia due to attainment of additional molecular lesions. We here describe the kinetics of a del(7q) driven leukemogenesis in a patient with multiple TET2 mutations and JAK2 V617F mutated...

Cite
Herborg LL, Nederby L, Kjeldsen E, et al. Kinetics of del(7q) driven leukemogenesis in a patient with JAK2 V617F and TET2 mutated chronic myeloproliferative neoplasm. Leuk Res Rep. 2013;2(2):51-3doi: 10.1016/j.lrr.2013.06.001.
Herborg, L. L., Nederby, L., Kjeldsen, E., Grønbæk, K., Hokland, P., Hansen, M., Celik Hansen, M., & Roug, A. S. (2013). Kinetics of del(7q) driven leukemogenesis in a patient with JAK2 V617F and TET2 mutated chronic myeloproliferative neoplasm. Leukemia research reports, 2(2), 51-3. https://doi.org/10.1016/j.lrr.2013.06.001
Herborg, Laura Laine, et al. "Kinetics of del(7q) driven leukemogenesis in a patient with JAK2 V617F and TET2 mutated chronic myeloproliferative neoplasm." Leukemia research reports vol. 2,2 (2013): 51-3. doi: https://doi.org/10.1016/j.lrr.2013.06.001
Herborg LL, Nederby L, Kjeldsen E, Grønbæk K, Hokland P, Hansen M, Celik Hansen M, Roug AS. Kinetics of del(7q) driven leukemogenesis in a patient with JAK2 V617F and TET2 mutated chronic myeloproliferative neoplasm. Leuk Res Rep. 2013 Jul 04;2(2):51-3. doi: 10.1016/j.lrr.2013.06.001. eCollection 2013. PMID: 24371780; PMCID: PMC3850390.
Copy Download .nbib Format: NLM
Short communications and case reports-Who cares?.

Leukemia research reports

Mundle S, Wetzler M.
PMID: 24371762
Leuk Res Rep. 2012 Nov 21;1(1):A1. doi: 10.1016/j.lrr.2012.11.001. eCollection 2012.

No abstract available.

Cite
Mundle S, Wetzler M. Short communications and case reports-Who cares?. Leuk Res Rep. 2012;1(1):A1doi: 10.1016/j.lrr.2012.11.001.
Mundle, S., & Wetzler, M. (2012). Short communications and case reports-Who cares?. Leukemia research reports, 1(1), A1. https://doi.org/10.1016/j.lrr.2012.11.001
Mundle, Suneel, and Wetzler, Meir. "Short communications and case reports-Who cares?." Leukemia research reports vol. 1,1 (2012): A1. doi: https://doi.org/10.1016/j.lrr.2012.11.001
Mundle S, Wetzler M. Short communications and case reports-Who cares?. Leuk Res Rep. 2012 Nov 21;1(1):A1. doi: 10.1016/j.lrr.2012.11.001. eCollection 2012. PMID: 24371762; PMCID: PMC3787822.
Copy Download .nbib Format: NLM
The use of low-dose protracted oral clofarabine in a patient with myelodysplastic syndrome after failing 5-azacitidine.

Leukemia research reports

Al Ustwani O, Greene JD, Wetzler M.
PMID: 24371774
Leuk Res Rep. 2013 Apr 30;2(1):34-5. doi: 10.1016/j.lrr.2013.03.002. eCollection 2013.

Patients with myelodysplastic syndrome who fail hypomethylating agents have a very short median survival and about 25% risk of disease transformation to acute myeloid leukemia. We report our experience with low-dose protracted oral clofarabine in one patient who achieved...

Cite
Al Ustwani O, Greene JD, Wetzler M. The use of low-dose protracted oral clofarabine in a patient with myelodysplastic syndrome after failing 5-azacitidine. Leuk Res Rep. 2013;2(1):34-5doi: 10.1016/j.lrr.2013.03.002.
Al Ustwani, O., Greene, J. D., & Wetzler, M. (2013). The use of low-dose protracted oral clofarabine in a patient with myelodysplastic syndrome after failing 5-azacitidine. Leukemia research reports, 2(1), 34-5. https://doi.org/10.1016/j.lrr.2013.03.002
Al Ustwani, Omar, et al. "The use of low-dose protracted oral clofarabine in a patient with myelodysplastic syndrome after failing 5-azacitidine." Leukemia research reports vol. 2,1 (2013): 34-5. doi: https://doi.org/10.1016/j.lrr.2013.03.002
Al Ustwani O, Greene JD, Wetzler M. The use of low-dose protracted oral clofarabine in a patient with myelodysplastic syndrome after failing 5-azacitidine. Leuk Res Rep. 2013 Apr 30;2(1):34-5. doi: 10.1016/j.lrr.2013.03.002. eCollection 2013. PMID: 24371774; PMCID: PMC3850391.
Copy Download .nbib Format: NLM
Translocation (8;21) acute myeloid leukemia presenting as severe aplastic anemia.

Leukemia research reports

Purev E, Dumitriu B, Hourigan CS, Young NS, Townsley DM.
PMID: 25003026
Leuk Res Rep. 2014 Jun 11;3(2):46-8. doi: 10.1016/j.lrr.2014.04.002. eCollection 2014.

We report a case of t(8;21) acute myeloid leukemia presenting as severe aplastic anemia. While initial bone marrow biopsy lacked any cytogenetic abnormalities in 20 analyzed metaphases, repeat bone marrow biopsy eight days later demonstrated this translocation. Initial cytogenetic...

Cite
Purev E, Dumitriu B, Hourigan CS, et al. Translocation (8;21) acute myeloid leukemia presenting as severe aplastic anemia. Leuk Res Rep. 2014;3(2):46-8doi: 10.1016/j.lrr.2014.04.002.
Purev, E., Dumitriu, B., Hourigan, C. S., Young, N. S., & Townsley, D. M. (2014). Translocation (8;21) acute myeloid leukemia presenting as severe aplastic anemia. Leukemia research reports, 3(2), 46-8. https://doi.org/10.1016/j.lrr.2014.04.002
Purev, Enkhtsetseg, et al. "Translocation (8;21) acute myeloid leukemia presenting as severe aplastic anemia." Leukemia research reports vol. 3,2 (2014): 46-8. doi: https://doi.org/10.1016/j.lrr.2014.04.002
Purev E, Dumitriu B, Hourigan CS, Young NS, Townsley DM. Translocation (8;21) acute myeloid leukemia presenting as severe aplastic anemia. Leuk Res Rep. 2014 Jun 11;3(2):46-8. doi: 10.1016/j.lrr.2014.04.002. eCollection 2014. PMID: 25003026; PMCID: PMC4081983.
Copy Download .nbib Format: NLM
Extracellular crystals in plasma cell myeloma.

Leukemia research reports

Brown JT, Burack WR, Becker MW, Vlad-Vonica R, Nadasdy T, Bennett JM, Mendler JH.
PMID: 25003027
Leuk Res Rep. 2014 Jun 18;3(2):49-50. doi: 10.1016/j.lrr.2014.04.004. eCollection 2014.

No abstract available.

Cite
Brown JT, Burack WR, Becker MW, et al. Extracellular crystals in plasma cell myeloma. Leuk Res Rep. 2014;3(2):49-50doi: 10.1016/j.lrr.2014.04.004.
Brown, J. T., Burack, W. R., Becker, M. W., Vlad-Vonica, R., Nadasdy, T., Bennett, J. M., & Mendler, J. H. (2014). Extracellular crystals in plasma cell myeloma. Leukemia research reports, 3(2), 49-50. https://doi.org/10.1016/j.lrr.2014.04.004
Brown, Jacqueline T, et al. "Extracellular crystals in plasma cell myeloma." Leukemia research reports vol. 3,2 (2014): 49-50. doi: https://doi.org/10.1016/j.lrr.2014.04.004
Brown JT, Burack WR, Becker MW, Vlad-Vonica R, Nadasdy T, Bennett JM, Mendler JH. Extracellular crystals in plasma cell myeloma. Leuk Res Rep. 2014 Jun 18;3(2):49-50. doi: 10.1016/j.lrr.2014.04.004. eCollection 2014. PMID: 25003027; PMCID: PMC4081982.
Copy Download .nbib Format: NLM
Linking the SUMO protease SENP5 to neutrophil differentiation of AML cells.

Leukemia research reports

Federzoni EA, Gloor S, Jin J, Shan-Krauer D, Fey MF, Torbett BE, Tschan MP.
PMID: 25984443
Leuk Res Rep. 2015 Apr 23;4(1):32-5. doi: 10.1016/j.lrr.2015.04.002. eCollection 2015.

In an mRNA profiling screen performed to unveil novel mechanisms of leukemogenesis, we found that the sentrin-specific protease 5 (SENP5) was significantly repressed in clinical acute myeloid leukemia when compared to healthy neutrophil samples. SENP5 is an enzyme that...

Cite
Federzoni EA, Gloor S, Jin J, et al. Linking the SUMO protease SENP5 to neutrophil differentiation of AML cells. Leuk Res Rep. 2015;4(1):32-5doi: 10.1016/j.lrr.2015.04.002.
Federzoni, E. A., Gloor, S., Jin, J., Shan-Krauer, D., Fey, M. F., Torbett, B. E., & Tschan, M. P. (2015). Linking the SUMO protease SENP5 to neutrophil differentiation of AML cells. Leukemia research reports, 4(1), 32-5. https://doi.org/10.1016/j.lrr.2015.04.002
Federzoni, Elena A, et al. "Linking the SUMO protease SENP5 to neutrophil differentiation of AML cells." Leukemia research reports vol. 4,1 (2015): 32-5. doi: https://doi.org/10.1016/j.lrr.2015.04.002
Federzoni EA, Gloor S, Jin J, Shan-Krauer D, Fey MF, Torbett BE, Tschan MP. Linking the SUMO protease SENP5 to neutrophil differentiation of AML cells. Leuk Res Rep. 2015 Apr 23;4(1):32-5. doi: 10.1016/j.lrr.2015.04.002. eCollection 2015. PMID: 25984443; PMCID: PMC4431638.
Copy Download .nbib Format: NLM
Prognostic impact of combined NPM1+/FLT3- genotype in patients with acute myeloid leukemia with intermediate risk cytogenetics stratified by age and treatment modalities.

Leukemia research

Hefazi M, Siddiqui M, Patnaik M, Wolanskyj A, Alkhateeb H, Zblewski D, Elliott M, Hogan W, Litzow M, Al-Kali A.
PMID: 26410460
Leuk Res. 2015 Sep 03; doi: 10.1016/j.leukres.2015.09.001. Epub 2015 Sep 03.

The prognostic impact of combined NPM1+/FLT3- genotype is not well defined in elderly patients with acute myeloid leukemia (AML), and in the setting of different treatments, such as cytotoxic chemotherapy (Chemo), hematopoietic cell transplantation (HCT), or hypomethylating agents (HMA)....

Cite
Hefazi M, Siddiqui M, Patnaik M, et al. Prognostic impact of combined NPM1+/FLT3- genotype in patients with acute myeloid leukemia with intermediate risk cytogenetics stratified by age and treatment modalities. Leuk Res. 2015;doi: 10.1016/j.leukres.2015.09.001.
Hefazi, M., Siddiqui, M., Patnaik, M., Wolanskyj, A., Alkhateeb, H., Zblewski, D., Elliott, M., Hogan, W., Litzow, M., & Al-Kali, A. (2015). Prognostic impact of combined NPM1+/FLT3- genotype in patients with acute myeloid leukemia with intermediate risk cytogenetics stratified by age and treatment modalities. Leukemia research, . https://doi.org/10.1016/j.leukres.2015.09.001
Hefazi, Mehrdad, et al. "Prognostic impact of combined NPM1+/FLT3- genotype in patients with acute myeloid leukemia with intermediate risk cytogenetics stratified by age and treatment modalities." Leukemia research vol. (2015). doi: https://doi.org/10.1016/j.leukres.2015.09.001
Hefazi M, Siddiqui M, Patnaik M, Wolanskyj A, Alkhateeb H, Zblewski D, Elliott M, Hogan W, Litzow M, Al-Kali A. Prognostic impact of combined NPM1+/FLT3- genotype in patients with acute myeloid leukemia with intermediate risk cytogenetics stratified by age and treatment modalities. Leuk Res. 2015 Sep 03; doi: 10.1016/j.leukres.2015.09.001. Epub 2015 Sep 03. PMID: 26410460.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 563 entries